Work

Paradigm Shifts in Diabetes Management: Key Highlights from the 2026 American Diabetes Association Standards of Care in Diabetes

Year: 2026

Type: article

Abstract: The ADA 2026 Standards of Care in Diabetes introduces pivotal updates that refine diagnostic and therapeutic workflows. Expanding upon the 2025 guidelines, the 2026 edition broadens continuous-glucose-monitoring (CGM) eligibility to include all individuals on insulin or non-insulin therapies where CGM aids management. Significant new guidance addresses hyperglycemia management in oncology, identifying metformin as the preferred first-line intervention for drug-induced glycemic excursions. Additionally, type 1-diabetes (T1D) risk stratification is refined; a confirmed single IA-2 autoantibody now warrants monitoring levels similar to the Stage 2 disease. Furthermore, prerequisites for automated-insulin-delivery (AID) initiation have been removed to streamline technology access. For laboratory professionals, these revisions emphasize the critical role of advanced glycemic metrics and precise autoantibody profiling in complex clinical contexts.

Source: LabMed

DOI: 10.3390/labmed3020010

Authors: Dipti Tiwari, Wann Jia Loh, Tar Choon Aw

Institutions: National University of Singapore, Changi General Hospital, SingHealth Duke-NUS Academic Medical Centre, Duke-NUS Medical School

Language: English

Topic: Diabetes Management and Research

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,207